Bioregenx, INC. (BRGX) — SEC Filings

Q: What are the key financial highlights for Bioregenx, INC.?

Key financial highlights for Bioregenx, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Bioregenx, INC.?

Key executives at Bioregenx, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Bioregenx, INC. stock?

Risk factors for Bioregenx, INC. (BRGX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Bioregenx, INC.?

Forward-looking statements and predictions from Bioregenx, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Bioregenx, INC.. Recent 10-K filing on Apr 15, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Bioregenx, INC. on SEC EDGAR

Overview

Bioregenx, INC. (BRGX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Apr 15, 2026: BioRegenx, Inc. filed its annual report on Form 10-K for the fiscal year ending December 31, 2025. The filing includes the company's financial statements, business descriptions, and certifications from its CEO and CFO. The company's principal executive offices and mailing address are located at 7407

Sentiment Summary

Across 22 filings, the sentiment breakdown is: 3 bearish, 19 neutral. The dominant filing sentiment for Bioregenx, INC. is neutral.

Filing Type Overview

Bioregenx, INC. (BRGX) has filed 3 10-K, 5 10-Q, 1 10-K/A, 8 8-K, 2 10-Q/A, 2 SC 13D/A, 1 SC 13D with the SEC between Apr 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (22)

BioRegenx Files 2025 Annual Report — 10-K · Apr 15, 2026 Risk: low
BioRegenx, Inc. filed its annual report on Form 10-K for the fiscal year ending December 31, 2025. The filing includes the company's financial statements, busin
BIOREGENX Narrows Loss Amidst Going Concern Doubts, Sales Dip — 10-Q · Nov 14, 2025 Risk: high
BIOREGENX, INC. (BRGX) reported a net loss of $525,764 for the nine months ended September 30, 2025, a significant improvement from the $4,653,446 net loss in t
BioRegenx Sales Dip 25% Amidst Persistent Going Concern Doubts — 10-Q · Aug 14, 2025 Risk: high
BIOREGENX, INC. (BRGX) reported a net loss of $445,199 for the six months ended June 30, 2025, a significant improvement from the $4,258,586 net loss in the pri
BioRegenx Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
BioRegenx, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2
BioRegenx Files Amended 2024 10-K with Equity Revisions — 10-K/A · Apr 16, 2025 Risk: medium
BioRegenx, Inc. filed an amended 10-K for the fiscal year ending December 31, 2024, on April 16, 2025. The filing includes revised financial statements, specifi
BioRegenx, Inc. Files 2024 Annual Report — 10-K · Apr 15, 2025 Risk: medium
BioRegenx, Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting its financial performance and business operations. The company, formerly
BioRegenx Reports Officer and Director Changes — 8-K · Apr 14, 2025 Risk: medium
BioRegenx, Inc. filed an 8-K on April 14, 2025, reporting changes effective April 4, 2025. The filing covers the departure of directors or certain officers, the
BioRegenx Announces Board and Executive Changes — 8-K · Jan 22, 2025 Risk: medium
BioRegenx, Inc. announced on January 15, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of c
BioRegenx, Inc. Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: low
BioRegenx, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as FindIt, Inc. and Artemis Energy Holdings, Inc., is incor
BioRegenx Announces Board and Executive Changes — 8-K · Oct 11, 2024 Risk: medium
BioRegenx, Inc. announced on October 7, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the
Bioregenx Files Q1 2024 10-Q Amendment — 10-Q/A · Oct 9, 2024 Risk: low
Bioregenx, Inc. filed an amended 10-Q for the period ending March 31, 2024. The filing includes financial data for the first quarter of 2024 and comparative per
BioRegenx Reports Director/Officer Changes & Compensation — 8-K · Jul 23, 2024 Risk: medium
BioRegenx, Inc. filed an 8-K on July 23, 2024, reporting events as of July 17, 2024. The filing pertains to the departure of directors or certain officers, the
Libertas Trust Amends BioRegenx Stake — SC 13D/A · Jul 22, 2024 Risk: medium
Libertas Trust, a group including Joseph S. Bird, Jr. and Suzanne Bird, has amended its Schedule 13D filing for BioRegenx, Inc. on July 22, 2024. The filing ind
Wilshire Holdings Trust Amends BioRegenx Stake Filing — SC 13D/A · Jul 19, 2024 Risk: medium
Wilshire Holdings Trust, a significant shareholder, filed an amendment to its Schedule 13D on July 19, 2024, regarding its holdings in BioRegenx, Inc. The filin
BioRegenx Announces Board Changes and Compensation Updates — 8-K · Jul 15, 2024 Risk: medium
BioRegenx, Inc. announced on July 13, 2024, a change in its board of directors. Specifically, the company reported the departure of a director and the election
BioRegenx Withdraws Previous Financial Statements — 8-K · Jun 11, 2024 Risk: high
BioRegenx, Inc. announced on June 7, 2024, that it will not rely on previously issued financial statements or any related audit report or completed interim revi
BioRegenx Files Q1 2024 10-Q Amendment — 10-Q/A · May 29, 2024 Risk: low
BioRegenx, Inc. filed an amended 10-Q for the period ending March 31, 2024. The filing includes financial data for the first quarter of 2024 and comparative per
BioRegenx Files Q1 2024 10-Q Report — 10-Q · May 24, 2024 Risk: low
BioRegenx, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2024. The company, formerly known as FindIt, Inc. and Artemis Energy Hold
BioRegenx Changes Auditors — 8-K · May 16, 2024 Risk: medium
BioRegenx, Inc. announced on May 15, 2024, that it has dismissed its former independent registered public accounting firm, BF Borgers CPA, PC. The company has a
Libertas Trust Files SC 13D for BioRegenx, Inc. — SC 13D · Apr 29, 2024 Risk: medium
On April 29, 2024, Libertas Trust, along with Joseph S. Bird, Jr. and Suzanne Bird, filed a Schedule 13D regarding their beneficial ownership of BioRegenx, Inc.
BIOREGENX, INC. Files 2023 Annual Report on Form 10-K — 10-K · Apr 12, 2024 Risk: low
BIOREGENX, INC. (BRGX) filed a Annual Report (10-K) with the SEC on April 12, 2024. BIOREGENX, INC. filed its annual report for the fiscal year ending December
BioRegenx Reports Asset Changes, Equity Sales, Control Shifts — 8-K · Apr 1, 2024 Risk: medium
BioRegenx, Inc. (formerly Findit, Inc.) filed an 8-K on March 29, 2024, reporting on events that occurred on March 8, 2024. The filing indicates a completion of

Risk Profile

Risk Assessment: Of BRGX's 22 recent filings, 3 were flagged as high-risk, 13 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Bioregenx, INC.'s most recent 10-Q filing (Nov 14, 2025):

Revenue: $1,468,872
Net Income: -$525,764
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $46,947
Operating Margin: -21.0%
Total Assets: $1,167,764
Total Debt: $4,814,900

Key Executives

Nevada
Joseph S. Bird, Jr.
Suzanne Bird
William Resides

Industry Context

BIOREGENX operates in a sector that often requires significant R&D investment and faces long development cycles. The industry is characterized by intense competition, regulatory hurdles, and the need for substantial capital to bring products to market. Companies in this space often rely on partnerships, licensing, or significant funding rounds to sustain operations.

Top Tags

financials (7) · 10-Q (5) · amendment (4) · 10-K (3) · management-change (3) · annual-report (2) · Going Concern (2) · Net Loss (2) · Liquidity Risk (2) · Defaulted Debt (2)

Key Numbers

iXBRL 10-K Size: 1054832 — Size of the interactive data document for the 10-K filing.
Documents: 79 — Total number of documents included in the submission.
Net loss for nine months ended Sep 30, 2025: $525,764 — Significant improvement from $4,653,446 net loss in prior year
Total assets as of Sep 30, 2025: $1,167,764 — Increased from $508,535 at Dec 31, 2024, driven by intangible assets
Total liabilities as of Sep 30, 2025: $4,814,900 — Increased from $3,887,794 at Dec 31, 2024
Notes payable in default: $522,500 — Indicates significant financial distress and going concern risk
Cash and cash equivalents as of Sep 30, 2025: $46,947 — Extremely low cash balance, highlighting liquidity issues
Net sales for nine months ended Sep 30, 2025: $1,468,872 — Decreased from $1,879,617 in the comparable 2024 period
Stockholders' deficit as of Sep 30, 2025: $(3,647,136) — Worsened from $(3,379,259) at Dec 31, 2024
Intangible assets, net as of Sep 30, 2025: $725,000 — New asset class not present at Dec 31, 2024, contributing to asset increase
Net loss for six months ended June 30, 2025: $445,199 — Improved from $4,258,586 in prior year, but still a loss.
Net sales for six months ended June 30, 2025: $961,116 — Decreased by 25.1% from $1,283,580 in prior year.
Stockholders' deficit as of June 30, 2025: $3,654,708 — Indicates negative equity and severe financial distress.
Cash and cash equivalents as of June 30, 2025: $46,456 — Extremely low liquidity, raising going concern doubts.
Notes payable in default as of June 30, 2025: $522,500 — Direct evidence of financial instability and default risk.

Related Companies

BIOX

Frequently Asked Questions

What are the latest SEC filings for Bioregenx, INC. (BRGX)?

Bioregenx, INC. has 22 recent SEC filings from Apr 2024 to Apr 2026, including 8 8-K, 5 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BRGX filings?

Across 22 filings, the sentiment breakdown is: 3 bearish, 19 neutral. The dominant sentiment is neutral.

Where can I find Bioregenx, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Bioregenx, INC. (BRGX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Bioregenx, INC.?

Key financial highlights from Bioregenx, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BRGX?

The investment thesis for BRGX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Bioregenx, INC.?

Key executives identified across Bioregenx, INC.'s filings include Nevada, Joseph S. Bird, Jr., Suzanne Bird, William Resides.

What are the main risk factors for Bioregenx, INC. stock?

Of BRGX's 22 assessed filings, 3 were flagged high-risk, 13 medium-risk, and 6 low-risk.

What are recent predictions and forward guidance from Bioregenx, INC.?

Forward guidance and predictions for Bioregenx, INC. are extracted from SEC filings as they are enriched.